Starting Oct. 1, Blue Cross Blue Shield Of Michigan And Blue Care Network Will Change The Prior Authorization Approval Criteria For Commercial PPO And HMO Plans For Weight Loss Drugs: Contrave, Generic Amphetamine Sulfate, Qsymia, Saxenda, Wegovy, Xenical
Portfolio Pulse from Benzinga Newsdesk
Blue Cross Blue Shield of Michigan and Blue Care Network will change the prior authorization approval criteria for commercial PPO and HMO plans for weight loss drugs, including Contrave, Generic Amphetamine Sulfate, Qsymia, Saxenda, Wegovy, and Xenical, starting October 1.
September 22, 2023 | 6:40 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Novo Nordisk, the manufacturer of Saxenda and Wegovy, may be impacted by the changes in approval criteria by Blue Cross Blue Shield of Michigan and Blue Care Network.
The changes in approval criteria could potentially affect the sales of Saxenda and Wegovy, two weight loss drugs manufactured by Novo Nordisk. However, the exact impact will depend on the specifics of the new criteria and how they are implemented.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 75
NEUTRAL IMPACT
WW International, formerly known as Weight Watchers, may be indirectly affected by the changes in approval criteria for weight loss drugs by Blue Cross Blue Shield of Michigan and Blue Care Network.
While WW International does not manufacture any of the drugs mentioned, changes in the approval and coverage of weight loss drugs could potentially affect the demand for their weight management services. The exact impact will depend on the specifics of the new criteria and how they are implemented.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50